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Abstract
The objective was to determine the impact of intact normoxic and hyperoxia-exposed (95% O2 for 48 h) bovine
pulmonary arterial endothelial cells in culture on the redox status of the coenzyme Q10 homolog coenzyme
Q1 (CoQ1). When CoQ1 (50 μM) was incubated with the cells for 30 min, its concentration in the medium
decreased over time, reaching a lower level for normoxic than hyperoxia-exposed cells. The decreases in
CoQ1 concentration were associated with generation of CoQ1 hydroquinone (CoQ1H2), wherein 3.4 times more
CoQ1H2 was produced in the normoxic than hyperoxia-exposed cell medium (8.2 ± 0.3 and 2.4 ± 0.4 μM, means ±
SE, respectively) after 30 min. The maximum CoQ1 reduction rate for the hyperoxia-exposed cells, measured
using the cell membrane-impermeant redox indicator potassium ferricyanide, was about one-half that of
normoxic cells (11.4 and 24.1 nmol·min−1·mg−1 cell protein, respectively). The mitochondrial electron transport
complex I inhibitor rotenone decreased the CoQ1 reduction rate by 85% in the normoxic cells and 44% in the
hyperoxia-exposed cells. There was little or no inhibitory effect of NAD(P)H:quinone oxidoreductase 1 (NQO1)
inhibitors on CoQ1 reduction. Intact cell oxygen consumption rates and complex I activities in mitochondriaenriched fractions were also lower for hyperoxia-exposed than normoxic cells. The implication is that intact
pulmonary endothelial cells influence the redox status of CoQ1 via complex I-mediated reduction to CoQ1H2,
which appears in the extracellular medium, and that the hyperoxic exposure decreases the overall
CoQ1 reduction capacity via a depression in complex I activity.
Among the metabolic functions of the pulmonary endothelium is the ability to influence the redox status and
disposition of redox active compounds such as quinones via the activity of endothelial surface and/or
intracellular quinone reductases, hydroquinone oxidases, and other redox processes (4, 28, 30). The size of the
pulmonary endothelial surface and its position in the circulation implicate this endothelial function as a
determinant in the bioactivity of various physiological, pharmacological, chemotherapeutic, xenobiotic, and
dietary redox active compounds in the lung, blood, and downstream vessels and organs.
The overall impact of the pulmonary endothelium on redox active substances depends on the properties of the
substances themselves (e.g., propensity to permeate cell membranes and to act as an electron acceptor for any
given reductase) as well as the properties of the pulmonary endothelial cells (e.g., activities and complement of
available redox enzymes). Thus, of the redox active compounds we have studied, including the quinones
coenzyme Q0 and duroquinone (DQ), and in the present study, coenzyme Q1 (CoQ1), the thiazine polymer
(TBOP), and potassium ferricyanide [K3Fe(CN)63−], their differing physical and chemical properties influence the
subcellular site of reduction, the electron donor utilized, the dominant reductase involved, and/or the effects of
metabolic or prosthetic group inhibitors (4, 9, 28–32). These diverse characteristics make such compounds
useful probes of redox function not only of pulmonary endothelial cells in culture but also in the intact perfused
rodent lung (2, 3, 5). With regard to the properties of the cells themselves, it is well known that expression
and/or activities of various pulmonary endothelial redox enzymes are influenced by pro-oxidant stimuli, with the
potential outcome being a change in pulmonary endothelial metabolism of redox active compounds
(10, 22, 26, 28).

These concepts are represented by the observation that when intact bovine pulmonary arterial cells were
incubated with 50 μM DQ, the two-electron reduction product durohydroquinone (DQH2) appeared in the
extracellular medium, with reduction effected primarily via the ubiquitous cytosolic quinone reductase
NAD(P)H:quinone oxidoreductase 1 (NQO1) (28, 30). Consistent with the fact that NQO1 is under transcriptional
control of the antioxidant response element (ARE), exposure of the cells to oxidant stress (hyperoxia, 95% O2 for
48 h) resulted in NQO1 induction, thereby doubling the capacity of the intact cells to generate extracellular
DQH2 when incubated with DQ (23, 28). Promotion of two-electron DQ reduction in the hyperoxia-exposed cells
provided increased competition for semiquinone production via one-electron reduction, illustrating one of the
classic protective effects of NQO1 (11). DQ was also reduced on passage through the circulation of the perfused
rat lung, and exposure of rats to hyperoxia (21 days; 85% O2) increased lung NQO1 protein, total activity, and DQ
reduction capacity (5).
A question raised by these observations is whether the effect of hyperoxia to increase the DQ reduction capacity
of intact pulmonary endothelial cells via NQO1 induction extends to other quinone substrates. We chose
CoQ1 for further study because it has been used as an amphipathic electron acceptor for various
oxidoreductases, including NQO1, as isolated enzymes or in subcellular fractions and has nearly the same water
and lipid solubility properties as DQ (8, 12, 16, 18, 33, 36). With respect to the reduction mechanism in intact
cells, an NQO1 contribution to CoQ1 hydroquinone (CoQ1H2) generation has been identified in rat hepatocytes
and astrocytes, and the protective effect of CoQ1 in complex I dysfunction in hepatocytes has been attributed to
NQO1-mediated CoQ1 reduction followed by CoQ1H2 oxidation at complex III (12). On the other hand,
transplasma membrane electron transport (TPMET) has been suggested as a mechanism for CoQ1 reduction in
intact human red blood cells, Hep G cells, and chick neurons (42, 44). As a CoQ10 homolog, CoQ1 is also a highly
effective NADH:ubiquinone oxidoreductase (mitochondrial electron transport complex I) substrate in
mitochondria or submitochondrial particles (27), but to our knowledge, a contribution of complex I to
CoQ1 reduction in intact cells has not been identified.
The goal of the present study was to determine whether CoQ1 is reduced in the presence of bovine pulmonary
arterial endothelial cells and, if so, to evaluate the redox processes involved and the effect of oxidative stress on
cellular reduction capacity. The focus was on the impact of the intact cells on CoQ1 redox status in the
extracellular medium. Hyperoxia was chosen as the oxidative stress to gain further insight into its effects on
quinone metabolism, wherein it was originally selected because extensive functional, molecular, and
morphological studies have revealed the pulmonary endothelium to be an initial and key target of hyperoxic
lung injury (14).

MATERIALS AND METHODS
CoQ1 [2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone], potassium hexocyanoferrate (III)
[K3Fe(CN)63−, hereafter referred to as ferricyanide or Fe(CN)63−], HEPES, and other reagents, unless otherwise
specified, were purchased from Sigma Chemical (St. Louis, MO) or Burdick and Jackson, the latter for HPLC
mobile phase reagents.
RPMI 1640 tissue culture medium and fetal calf serum were obtained from Invitrogen (Carlsbad, CA). Biosilon
microcarrier beads were obtained from Nunc (Roskilde, Denmark). Protein determinations were performed
using the Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA). CoQ1H2 was prepared by reduction
of CoQ1 with potassium borohydride as previously reported (28). The mechanism-based irreversible NQO1
inhibitor ES936 was the kind gift of Drs. David Siegel and David Roth (School of Pharmacy, University of Colorado
Health Sciences Center, Denver, CO) (15). Toluidine blue O was incorporated in an acrylamide polymer by
copolymerization of toluidine blue O methylacrylamide and acrylamide to prepare the toluidine blue O
polyacrylamide (TBOP), as previously described (9). The amount of reducible toluidine blue O (TBOP+) per unit

mass of the TBOP preparation used in the current study was ∼17 nmol/mg, determined as described previously
(9).

Endothelial cell culture.

Bovine pulmonary arterial endothelial cells were isolated from segments of calf pulmonary artery obtained from
a local slaughterhouse, and cells between passages 4 and 20 were grown to confluence (determined by phasecontrast microscopy) on gelatin-coated Biosilon microcarrier beads (mean diameter 230 μm; surface area 255
cm2/g beads) in magnetic stirrer bottles (Techne, Burlington, NJ) containing RPMI 1640 medium supplemented
with 20% fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 30 mg/ml l-glutamine as previously
described (31).
The hyperoxic exposure was accomplished as previously described by connecting a gas tank filled with 95% O25% CO2 to one of the side arms of the culture stirrer bottles by a length of tubing that was fitted through an
opening in the back wall of the incubator (28). The other side arm was fitted with tubing that exited the
incubator opening and was immersed in water to a depth of ∼3 cm. The latter was to allow for visualization of
gas flow through the bottle via bubble formation in the water. The gas flow rate was ∼5 ml/min over a period of
∼24–72 h, with the time interval between 48 and 54 h designated hereafter as hyperoxia exposed. The
normoxic cells were exposed to the incubator gas mixture (95% air-5% CO2). After 24 h of gassing, this procedure
resulted in cell medium Po2 of 550.9 ± 15.5 and 122.9 ± 1.1 mmHg (means ± SE), Pco2 of 35.2 ± 0.2 and 34.8 ± 0.3
mmHg, and pH values of 7.24 ± 0.10 and 7.31 ± 0.10 for the hyperoxia-exposed and normoxic exposures,
respectively (n = 4).

Protocols for measuring reduction of CoQ1 and other electron acceptors (DQ and TBOP+)
by intact cells.
For each experimental sample, ∼0.3-ml packed volume of cell-coated beads (160 cm2 cell culture surface
area/ml beads) was aliquoted into a 55 × 10 × 10-mm acrylic spectrophotometric cuvette (Sarstedt, Newton,
NC). After the cell-coated beads had settled, they were washed three consecutive times by resuspension in 3 ml
of room air-saturated Hanks' balanced salt solution (HBSS) containing 5.5 mM glucose and 10 mM HEPES
(HBSS/HEPES), pH 7.4, and the beads were allowed to settle between each wash. The HBSS/HEPES was the
experimental medium in all experiments that follow.

The washed cell-coated beads were resuspended in 3 ml of room air-saturated HBSS/HEPES at 37°C containing
CoQ1 (50 μM) and allowed to settle below the level of the spectrophotometer light path. The absorbance
spectrum of the medium was measured between 250 and 350 nm by using a model DU 7400
spectrophotometer (Beckman Coulter). The capped cuvettes were placed on a Nutator mixer in a 37°C
incubator, and periodically, the mixing was stopped and the cell-coated beads were allowed to settle for
measurement of the medium absorbance spectrum. At the end of the incubation period, the medium was
removed from the cells, and H2O2 (final concentration 0.1 mM) and peroxidase (final concentration 1.48 U/ml)
were added to the cell-free medium to oxidize any CoQ1H2 to CoQ1. The absorbance spectrum was measured
again to determine the total concentration of CoQ1 present, and the difference between the CoQ1 concentration
before and after the oxidation procedure was used to determine the CoQ1H2 concentration that was in the
medium surrounding the cells at the end of the 30-min incubation period. The concentrations of CoQ1 were
calculated as the difference between the absorbance values at 281 and 294 nm to correct for crossover from
CoQ1H2 absorbance, using the extinction coefficient 8.27 mM−1·cm−1. The same protocol was used in an
additional study with the cuvettes only, without cells present, to control for nonspecific association of CoQ1 with
the cuvettes.

CoQ1-, DQ-, or TBOP+-mediated reduction of the cell membrane-impermeant secondary electron acceptor
ferricyanide was measured using protocols previously described for DQ and TBOP+ (9, 28–31). After the cellcoated beads were washed free of culture medium as described above, 3 ml of HBSS/HEPES containing 600 μM
ferricyanide in the absence or presence of CoQ1 (1–50 μM), DQ (50 μM), or TBOP (0.2 mg/ml) were added to the
cells. The cells were mixed with the medium as described above, and periodically the mixing was stopped and
the absorbance of ferricyanide in the medium measured at 421 nm. The amount of the ferricyanide reduction
product, ferrocyanide [Fe(CN)64−] was calculated from the decrease in ferricyanide absorbance at each time
point (extinction coefficient 1.0 mM−1·cm−1). Additional experiments utilizing the ferricyanide protocol were
performed in which the NQO1 inhibitors dicumarol (10 μM) or ES936 (0.5 μM) or the complex I inhibitor
rotenone (1 μM) was added to the medium along with the ferricyanide and CoQ1 or DQ.
CoQ1-, DQ-, or TBOP+-mediated ferricyanide reduction rates were determined from linear regression fits to the
individual ferricyanide vs. time curves (9, 28–31). The background rates of cell-mediated ferricyanide reduction
in the absence of CoQ1, DQ, or TBOP were subtracted from the individual rates obtained in their presence and
normalized to the cell protein, and then the data from the individual experiments were combined to obtain
mean rates. The reduction rates for CoQ1, DQ or TBOP+ were calculated as one-half the zero-order ferricyanide
reduction rates in the presence of the electron acceptors. The underlying assumptions are that CoQ1 and DQ are
freely permeable to intracellular sites of reduction and that CoQ1H2 and DQH2 are freely permeable to
intracellular sites of oxidation, whereas TBOP+ is reduced at the cell surface via TPMET (9, 28). The assumption
that both CoQ1 and CoQ1H2 are freely cell membrane permeant is based on their high octanol:water partition
coefficients [log10 octanol:water partition coefficient >3 for both redox forms (37)] and studies in the perfused
rat lung (unpublished data) revealing a “flow-limited” behavior for CoQ1H2, consistent with freely permeating
access to lung tissue from the vascular space. An additional assumption is that since ferricyanide reduction by
CoQ1H2, DQH2, and the reduced form of TBOP+, TBOPH, is virtually instantaneous on the time course of the
experiments, ferricyanide acts as an extracellular sink for the hydroquinones or TBOPH generated by the cells,
thereby minimizing the contribution of cell-mediated oxidation of CoQ1H2, DQH2, or TBOPH to the net effect of
the cells on the compounds (9, 28–31).

HPLC measurements of CoQ1 and CoQ1H2.

HPLC measurements of medium CoQ1 and CoQ1H2 concentrations following 30-min incubations of the cells with
CoQ1 were carried out under the incubation conditions described above, using a previously described HPLC
system (4, 30). CoQ1 and CoQ1H2 were separated using a Supelcosil octadecylsilane LC-18-T (3-μm particle size,
150 × 4.6 mm) column eluted with methanol-H2O-trifluoroacetic acid (70:30:0.1 vol/vol/vol) containing 50 mM
acetic acid. The mobile phase was continuously sparged with N2 for at least 15 h before and throughout the
course of the HPLC studies. The CoQ1 in the column eluate was measured by absorbance at 270 nm. CoQ1H2 was
detected electrochemically, with the potentials at the first and second analytical electrodes set at −250 and
+500 mV, respectively. The first electrode served as a screen electrode to prevent interference from compounds
that might coelute with CoQ1H2 but have a lower oxidation potential. The CoQ1H2 was oxidized at the second
electrode. The elution times were 7.86 ± 0.04 min for CoQ1 and 5.21 ± 0.02 min for CoQ1H2 for 12 injections
each.
The concentration of CoQ1 was determined by peak area quantification against a standard curve. To account for
any CoQ1 present in the CoQ1H2 standards (typically ∼5–10% of the total), the CoQ1H2 standard curve was
calibrated by determining the CoQ1 concentration in each standard, as measured by HPLC, before and after the
addition of H2O2 (final concentration 0.1 mM) and peroxidase (final concentration 1.48 U/ml), to fully oxidize the
sample. The standard curves were linear over the CoQ1 and CoQ1H2 concentration ranges studied.

Protocols for measuring CoQ1H2 oxidation by intact cells.

Cell-coated beads in spectrophotometric cuvettes were washed free of culture medium and resuspended in 3 ml
of room air-saturated HBSS/HEPES containing CoQ1H2 (50 μM) without and with the addition of the
mitochondrial electron transport complex III inhibitors myxothiazol (2 μM) and antimcycin A (2 μM). The cellcoated beads were allowed to settle below the level of the spectrophotometer light path, and the absorbance
spectrum of the medium was measured between 250 and 350 nm. The capped cuvettes were placed on a
Nutator mixer in a 37°C incubator, and periodically, the mixing was stopped and the cell-coated beads were
allowed to settle for measurement of the medium absorbance spectrum. CoQ1 concentrations were determined
as described above. CoQ1H2 autooxidation under the study conditions was evaluated using the same protocol,
except that there were no cells present.

Complex I and complex IV (cytochrome oxidase) activity assays.
A ∼3-ml packed volume of cell-coated beads was washed by resuspension and settling in 5 ml of phosphatebuffered saline (PBS), followed by 5 ml of Dulbecco's phosphate-buffered saline (D-PBS) containing 0.5 mM
EDTA. The cells were detached from the microcarrier beads by trypsinization. The mitochondria-enriched
fractions were prepared from the cells using the mitochondria isolation kit for cultured cells (catalog no. 89874;
Pierce, Rockford IL) essentially as described by the manufacturer, following option B, and using a Wheaton
Potter-Elvehjem tissue grinder to disrupt the cells (60 strokes). For 21 preparations from normoxic and
hyperoxia-exposed cells, the mitochondria-enriched fraction protein collected was 0.42 ± 0.06 mg. The
mitochondrial preparations were frozen at −80°C. Assay of complex I was as described previously (27), wherein
∼0.2 mg of the thawed mitochondria-enriched fraction was mixed in a solution containing 50 mM KCl, 1 mM
EDTA, 10 mM Tris·HCl, 1 mM cyanide, and 10 μM antimycin (pH 7.4) in the presence or absence of rotenone (20
μM) or rolliniastatin-2 (3 μM), the latter of which was the kind gift of Dr. Giorgio Lenaz (Dipartimento di
Biochimica, Universitá de Bologna, Bologna, Italy). Reactions were carried out at room temperature and initiated
by addition of NADH (final concentration 100 μM) and CoQ1 (final concentration 100 μM). The decrease in
absorbance at 340 nm was used to calculate the NADH oxidation rate using an extinction coefficient of 6.22
mM−1·cm−1. The rates were normalized to milligrams of mitochondria-enriched fraction protein, and the complex
I activity was calculated by subtracting the NADH oxidation rates measured in the absence and presence of the
complex I inhibitors.
Complex IV activity was determined as described previously (43). Ferrocytochrome c was mixed with ∼0.04 mg
of thawed mitochondria-enriched fraction protein in phosphate buffer containing 0.1% Triton X-100 (pH 6.2) at
room temperature, and the decrease in absorbance was measured at 550 nm. The ferrocytochrome c oxidation
rate was determined using an extinction coefficient of 19.1 mM−1·cm−1 and normalized to milligrams of
mitochondria-enriched fraction protein.

Cellular oxygen consumption.

Cellular oxygen consumption was measured using a Yellow Springs Instruments model 5300 biological oxygen
monitor (YSI, Yellow Springs, OH) as previously described (28, 30). Cell-coated beads were added to 3 ml of airsaturated HBSS/HEPES (initial O2 concentration 224 μM) in sealed magnetically stirred chambers at 37°C. Data
collection rate was every 2 s (DATAQ Instruments, Akron, OH). The rate of oxygen consumption was calculated
as the decrease in buffer O2 concentration over a period of ∼15 min following the addition of cells to the
chamber and over the same time period following additions of rotenone (5 μM) or 2,4-dinitrophenol (DNP; 50
μM) to the cell suspensions in the oximeter chambers.

Cell viability and protein content.

At the end of the experiments, for each cell sample, the medium was removed from the cells and the cells were
lysed by sonication as previously described (9, 28–31). Lactate dehydrogenase (LDH) activity in the medium and
cells lysate was determined as described, and the cell lysate protein content was measured using the Bio-Rad
protein assay (9, 28–31).

Statistical analysis.

Mean values for normoxic and hyperoxia-exposed cell treatments were compared using the Student's t-test or
ANOVA followed by Tukey's post hoc test. Differences were considered significant at the P < 0.05 level.

RESULTS

Figure 1A shows spectrophotometric measurements of CoQ1 concentrations in the medium of normoxic and
hyperoxia-exposed cells incubated with 50 μM CoQ1 for 30 min. The medium CoQ1 concentrations decreased
over time, reaching a lower level for the normoxic than hyperoxia-exposed cells by 5 min and remaining lower
for the normoxic cells throughout the incubation period. The decreases were in part attributable to celldependent reduction of CoQ1 to the hydroquinone (CoQ1H2), wherein the normoxic cells generated ∼3.4 times
more extracellular CoQ1H2 than the hyperoxia-exposed cells by the end of the 30-min incubation period (Fig. 1B).

Fig. 1.Spectrophotometric measurements of coenzyme Q1 (CoQ1) and CoQ1 hydroquinone (CoQ1H2) in medium
surrounding normoxic and hyperoxia-exposed pulmonary arterial endothelial cells incubated with CoQ1. A:
CoQ1 concentrations in the medium of normoxic and hyperoxia-exposed cell-coated microcarrier beads after
addition of 50 μM CoQ1. Also shown are the CoQ1 concentrations in the medium over the same experimental
time course in the absence of cells. Data are means ± SE for n = 5 each for the normoxic and hyperoxia-exposed
cells and n = 6 for the medium without cells. Cell proteins (means ± SE) were 1.51 ± 0.06 and 1.60 ± 0.08 mg for
the normoxic and hyperoxia-exposed cells, respectively. *P < 0.05, significantly different from the
CoQ1 concentration in the normoxic cell medium at the corresponding time point. B: CoQ1H2 concentrations in
the medium at the end of the 30-min incubation period in A. *P < 0.05, significantly different from the
CoQ1H2 concentration in the normoxic cell medium.
As shown in Fig. 1, the CoQ1 concentration in the medium also decreased over the experimental time course
even in the absence of cells, wherein 72.1 ± 0.5% of the CoQ1 originally added to the medium was remaining at
the end of the 30-min incubation period. This was analogous to observations with DQ, wherein the loss was
attributed to binding to the experimental plasticware (30). Of the CoQ1 originally added to the normoxic and
hyperoxia-exposed cell medium, 68.9 ± 3.0 and 67.8 ± 3.4%, respectively, was recovered in the extracellular
medium as CoQ1 + CoQ1H2 at the end of the 30-min incubation period. The percent recoveries in the absence
and presence of cells were not significantly different (ANOVA, P = 0.44), suggesting that the incomplete recovery
in the medium surrounding the cells was attributable predominately to CoQ1 binding to the plasticware.

Figure 2 shows HPLC measurements of CoQ1 and CoQ1H2 in the medium of normoxic and hyperoxia-exposed
cells after 15 min of incubation with 50 μM CoQ1 under the same conditions as in Fig. 1. About 3.5 times more
CoQ1H2 was detected in the medium surrounding the normoxic than the hyperoxia-exposed cells, which was
consistent with the spectrophotometric measurements in Fig. 1B.

Fig. 2.HPLC measurements of CoQ1H2 and CoQ1 in medium surrounding normoxic and hyperoxia-exposed
pulmonary arterial endothelial cells incubated with CoQ1 (50 μM). CoQ1H2 and CoQ1 standards were 39.4 and
50.2 μM, respectively. After 15 min of incubation under the same conditions as described in Fig. 1, the cell
medium concentrations of CoQ1H2 and CoQ1 were 7.3 and 19.5 μM, respectively, for the normoxic cells and 2.1
and 25.6 μM, respectively, for the hyperoxia-exposed cells. The 2 detector signals were scaled such that the area
of the CoQ1 peak = area of CoQ1H2 peak at equimolar concentrations. Cell proteins were 0.8 and 0.7 mg for the
normoxic and hyperoxia-exposed cells, respectively.
Figure 3 shows spectrophotometric measurements of CoQ1 concentrations in the medium of normoxic and
hyperoxia-exposed cells incubated with 50 μM CoQ1H2 for 30 min. The medium CoQ1 concentrations increased
at a similar rate for the normoxic and hyperoxia-exposed cells for the first ∼5 min, after which time they tended
to level off, albeit at a lower concentration for the normoxic than hyperoxia-exposed cells. There was no
significant difference between the amount of total CoQ1 + CoQ1H2 recovered in the medium at the end of the
30-min incubation period for the normoxic and hyperoxia-exposed cells (P > 0.05). The generation of CoQ1 from
CoQ1H2 was primarily cell dependent, since the CoQ1H2 autooxidation rate in the absence of cells was relatively
very slow (Fig. 3). The mitochondrial electron transport complex III inhibitors myxothiazol (2 μM) and antimycin
A (2 μM) largely blocked the appearance of CoQ1 when normoxic or hyperoxia-exposed cells were incubated
with CoQ1H2, suggesting complex III as the dominant site of CoQ1H2 oxidation.

Fig. 3.Spectrophotometric measurements of CoQ1 in medium surrounding normoxic and hyperoxia-exposed
pulmonary arterial endothelial cells incubated with CoQ1H2. CoQ1 concentrations were measured in the medium
after the addition of 50 μM CoQ1H2 to the normoxic and hyperoxia-exposed cell-coated microcarrier beads
without and with the complex III inhibitors myxothiazol (2 μM) and antimycin A (2 μM). Also shown are the
CoQ1 concentrations in the medium in the absence of cells. Data are means ± SE for n = 3 each. Cell proteins
(means ± SE) were 0.67 ± 0.03, 0.73 ± 0.02, 0.69 ± 0.02, and 0.71 ± 0.01 mg for the normoxic, hyperoxiaexposed, normoxic + myxothiazol + antimycin A, and hyperoxia-exposed + myxothiazol + antimycin A cells,
respectively. *P < 0.05, significantly different from the CoQ1 concentration in the normoxic cell medium at the
corresponding time point.
Together, the data in Figs. 1–3 suggested that the impact of the cells on CoQ1 and CoQ1H2 was a result of both
CoQ1 reduction and CoQ1H2 oxidation reactions. The net effect was that regardless of whether CoQ1 or
CoQ1H2 was initially added, the CoQ1 concentration approached a quasi-steady state that was higher for
hyperoxia-exposed than normoxic cells. Since the small difference between the quasi-steady-state
CoQ1 concentrations attained for the normoxic and hyperoxia-exposed cells [∼5 μM CoQ1 (Fig. 1 or 3)] could
potentially mask a large difference in CoQ1 reduction and/or CoQ1 oxidation rate(s), a means to separate the
two rates was required to interpret the data. The secondary cell membrane impermeant redox indicator
ferricyanide has proved useful for unmasking the quinone reduction component from the net effect of the cells
on the quinones by minimizing the contribution of cell-mediated hydroquinone oxidation. It does so by virtually
instantaneously oxidizing cell-generated hydroquinone, acting as a hydroquinone sink. The ferricyanide
reduction rate thereby provides an estimation of the rate of hydroquinone appearance, or quinone reduction
(see materials and methods and Refs. 9, 28–31).
Figure 4A shows that ferricyanide reduction by normoxic or hyperoxia-exposed cells proceeded relatively slowly
in the absence of CoQ1. However, when 50 μM CoQ1 was present along with ferricyanide, the amount of
ferricyanide in the medium decreased over time. This was indicative of ferricyanide reduction to ferrocyanide by
the cell-generated CoQ1H2, wherein the net reaction followed zero-order kinetics (Fig. 4A). The rate of
CoQ1 reduction to CoQ1H2, calculated as one-half the CoQ1-mediated ferricyanide reduction rate, was about
twice as fast for the normoxic as the hyperoxia-exposed cells (Fig. 4B). When studied over the

CoQ1 concentration range of 1–50 μM, the normoxic cell-mediated CoQ1 reduction rates were faster than the
hyperoxia-exposed cells at concentrations >10 μM (Fig. 5). The decrease in CoQ1 reduction capacity in the
hyperoxia-exposed cells was not associated with a detectable decrease in cell protein, cell viability measured as
%LDH release, or total LDH activity compared with normoxic cells (Table 1). Furthermore, the effect on CoQ1 was
apparently not indicative of a general decline in cell redox function, since the DQ reduction rate as a measure of
NQO1 activity was higher for the hyperoxia-exposed than normoxic cells (Fig. 6, A and B), consistent with our
previous observations (28, 30), whereas TPMET-mediated TBOP+ reduction rates were comparable for the
normoxic and hyperoxia-exposed cells (Fig. 6, C and D).

Fig. 4.CoQ1 reduction by normoxic and hyperoxia-exposed cells measured using ferricyanide. A: decrease in total
ferricyanide in the medium after addition of either ferricyanide (600 μM) alone or ferricyanide (600 μM) +
CoQ1 (50 μM) to the extracellular medium. Data are means ± SE for n = 17 each for the normoxic and hyperoxiaexposed cell studies with CoQ1 and n = 4 each without CoQ1. The lines are linear regression fits to the data. Cell
proteins (means ± SE) for the normoxic and hyperoxia-exposed cell studies with CoQ1 were 1.72 ± 0.31 and 1.78
± 0.3 mg, respectively, and 1.84 ± 0.13 and 1.80 ± 0.14 mg, respectively, without CoQ1. B: CoQ1 reduction rates
were obtained from independent linear regression model fits to 17 normoxic and 17 hyperoxia-exposed cell data
sets, with the mean ferricyanide-only rate (n = 4) subtracted from each, with each of the resulting rates
normalized to cell protein. Data are means ± SE of the CoQ1 reduction rates, which were calculated as one-half
the zero-order CoQ1-mediated ferricyanide reduction rates, under assumptions stated in materials and
methods and in Refs. 38 and 40. *P < 0.05, significantly different from normoxic cells.

Fig. 5.Effect of CoQ1 concentration on CoQ1 reduction rates in normoxic and hyperoxia-exposed cells. The
reduction rates of CoQ1 (1–50 μM) measured using 600 μM ferricyanide and normalized to cell protein. Data
represent the CoQ1 reduction rates, calculated as described in Fig. 4 from the mean ± SE of n = 4 each normoxic
and hyperoxia-exposed cell CoQ1 concentration response curves, for a total of 23 data points for each cell type.
The lines represent Michaelis-Menten model fits to the data. The estimated values of Vmax from the model fit to

the data were 24.1 and 11.4 nmol·min−1·mg cell protein−1, and the estimated Km values were 8.9 and 2.0 μM for
the normoxic and hyperoxia-exposed cells, respectively. Cell proteins (means ± SE) for the normoxic and
hyperoxia-exposed cell studies were 1.78 ± 0.13 and 1.88 ± 0.14 mg, respectively. *P < 0.05, significantly
different from normoxic cells at the same CoQ1 concentration.

Fig. 6.Duroquinone (DQ) and toluidine blue O polyacrylamide (TBOP+) reduction by normoxic and hyperoxiaexposed cells measured using ferricyanide. The total medium ferricyanide following addition of 600 μM
ferricyanide and 50 μM DQ (A) or 600 μM ferricyanide and 0.2 mg/ml TBOP (C) to the normoxic and hyperoxiaexposed cells. Data are means ± SE from n = 4 each of the normoxic and hyperoxia-exposed cell studies. The
lines represent linear regression fits to the data. Cell proteins (means ± SE) were 1.70 ± 0.2 and 1.75 ± 0.15 mg
(A) and 1.63 ± 0.13 and 1.73 ± 0.14 mg (C) for the normoxic and hyperoxia-exposed cells, respectively. B and D:
DQ and TBOP+ reduction rates (means ± SE), respectively, obtained from the data in A and C, as described in the
legend to Fig. 4 for CoQ1. *P < 0.05, significantly different from normoxic cells.
Table 1. Normoxic and hyperoxia-exposed cell protein, cell viability (%LDH release), and total cell LDH activity
Cell Protein,
Cell Viability, %LDH Total Cell LDH Activity,
Total Cell LDH Activity,
g/cm2
release
units/ g protein
units/cm2
Normoxic
30.7±1.1
2.6±0.2
3.0±0.1
90.3±3.4
Hyperoxia31.4±1.1
2.8±0.2
3.1±0.1
95.5±3.7
exposed
Data are means ± SE (n = 77 for each measurement) of normoxic and hyperoxia-exposed (95% O2, 48 h) cell
protein normalized to cell culture surface area, cell viability measured as the percentage of total cell lactate
dehydrogenase (LDH) released from the cells into the medium and total cell LDH activity normalized to cell
protein or cell culture surface area. No significant differences between groups by t-test (P > 0.05).

Quinone reductase inhibitors were used to evaluate the mechanism(s) of pulmonary endothelial cell-mediated
CoQ1 reduction. There was no significant effect of the competitive and mechanism-based NQO1 inhibitors
dicumarol or ES936, respectively, on CoQ1 reduction rates for the normoxic cells (Fig. 7, A and C) and little, if
any, for the hyperoxia-exposed cells (Fig. 7, B and D). Yet, the same concentration of dicumarol nearly
completely blocked DQ reduction in both normoxic and hyperoxia-exposed cells, consistent with previous
observations (Fig. 7, E and F) (28, 30). On the other hand, the mitochondrial electron transport complex I
inhibitor rotenone decreased the CoQ1 reduction rate in both normoxic and hyperoxia-exposed cells (Fig. 8).
Rotenone decreased the normoxic cell mediated reduction rate from 22.3 to 3.2 nmol·min−1·mg cell
protein−1 (Fig. 8A) and the hyperoxia-exposed cell rate from 10.1 to 5.7 nmol·min−1·mg cell protein−1 (Fig. 8B).

Fig. 7.Effect of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibition on CoQ1 and DQ reduction rates in
normoxic and hyperoxia-exposed cells. A–D: CoQ1 reduction by normoxic (A) and hyperoxia-exposed cells (B)
without and with dicumarol (10 μM) and by normoxic (C) and hyperoxia-exposed cells (D) without and with
ES936 (0.5 μM). E and F: DQ reduction by normoxic (E) and hyperoxia-exposed cells (F) without and with
dicumarol (10 μM). Reduction rates were determined using 600 μM ferricyanide and 50 μM CoQ1 or DQ and
normalized to cell protein as described for Fig. 4. Cell proteins (means ± SE), without and with inhibitors,
respectively, were 1.98 ± 0.4 and 1.81 ± 0.22 mg (A), 1.75 ± 0.25 and 1.78 ± 0.26 mg (B), 2.06 ± 0.27 and 2.22 ±
0.32 mg (C), 1.95 ± 0.11 and 2.06 ± 0.23 mg (D), 2.21 ± 0.34 and 2.11 ± 0.33 mg (E), and 2.48 ± 0.27 and 2.27 ±
0.30 mg (F). The number of experiments was n = 6 each in A and B, n = 4 each in C and D, and n = 3 each
in E and F. *P < 0.05, significantly different from values without dicumarol or ES936.

Fig. 8.Effect of complex I inhibition on CoQ1 reduction rates in normoxic and hyperoxia-exposed cells. Reduction
rate of 50 μM CoQ1 normalized to cell protein by normoxic (A) and hyperoxia-exposed cells (B) without and with
rotenone (1 μM). Reduction rates were determined using 50 μM CoQ1 and 600 μM ferricyanide as described
for Fig. 4. Cell proteins (means ± SE) without and with rotenone, respectively, were 1.77 ± 0.2 and 1.59 ± 0.17
mg for normoxic cells and 1.83 ± 0.28 and 1.77 ± 0.33 mg for hyperoxia-exposed cells. The number of
experiments was n = 6 for each condition. *P < 0.05, significantly different from values without rotenone.
The effect of rotenone implied a role of complex I in CoQ1 reduction, with the decrease in rotenone-sensitive
reduction capacity in the hyperoxia-exposed cells suggesting a decrease in complex I activity. That the hyperoxic
response included altered mitochondrial quinone oxidoreductase activity was further suggested by the
observation that basal oxygen consumption was lower in the hyperoxia-exposed cells (Fig. 9, A and B). As shown
in the example in Fig. 9A, rotenone nearly completely blocked oxygen consumption in both normoxic and
hyperoxia-exposed cells, whereas the pharmacological uncoupler DNP increased the oxygen consumption rate in
normoxic but not hyperoxia-exposed cells. The rotenone-sensitive oxygen consumption rates in the absence and
presence of DNP for the entire data set are summarized in Fig. 9B.

Fig. 9.Oxygen consumption by intact normoxic and hyperoxia-exposed cells. A: a representative tracing of
oxygen consumption by normoxic and hyperoxia-exposed cells. At left, measurement of background oxygen
consumption (in the absence of cells) was followed by addition of the cells to the oximeter chambers at a and
rotenone at b. Cell proteins were 1.15 and 1.71 mg for the normoxic and hyperoxia-exposed cells, respectively.
At right, measurement of the background oxygen consumption in the absence of cells was followed by addition
of cells at a, 2,4-dinitrophenol (DNP; 50 μM) at c, and rotenone (5 μM) at b. Cell proteins were 1.23 and 1.60 mg

for the normoxic and hyperoxia-exposed cells, respectively. B: rotenone-sensitive oxygen consumption rates
(means ± SE) for normoxic (n = 12), hyperoxia-exposed (n = 6), normoxic + DNP (n = 9) and hyperoxia-exposed +
DNP cells (n = 6). Cell proteins (means ± SE) were 1.34 ± 0.09, 1.78 ± 0.05, 1.20 ± 0.08, and 1.70 ± 0.02 mg for the
normoxic, hyperoxia-exposed, normoxic +DNP and hyperoxia-exposed + DNP cells, respectively. *P < 0.05,
significantly different from normoxic cells. †P < 0.05, hyperoxia-exposed + DNP vs. normoxic cells + DNP (2-way
ANOVA and post hoc Tukey's test).
Consistent with the CoQ1 reduction and oxygen consumption studies, complex I activity in mitochondriaenriched fractions from hyperoxia-exposed cells was lower than that measured in fractions from normoxic cells
(Fig. 10A). However, there was no detectable difference between the normoxic and hyperoxia-exposed cell
complex IV activities in the mitochondria-enriched fractions (Fig. 10B).

Fig. 10.Complex I and IV activity in mitochondria-enriched fractions from normoxic and hyperoxia-exposed
cells. A: complex I activities for normoxic (n = 8) and hyperoxia-exposed (n = 9) cells. B: complex IV activities for
normoxic and hyperoxia-exposed cells (n = 4 each). *P < 0.05, significantly different from normoxic cells.
Whereas the studies in Figs. 1–10 were focused on 48 h of hyperoxic exposure, the data in Fig. 11 show that the
effect of hyperoxia on CoQ1 reduction was evident by 24 h of exposure, with no additional effects up to 72 h
(Fig. 11A). In contrast to the time course and direction of the hyperoxic effect on CoQ1 reduction, the hyperoxiainduced increase in DQ reduction rate was not observed until 48 h of exposure, with a further increase seen at
72 h (Fig. 11, A and B). There was no detectable effect of hyperoxia on TBOP+ reduction via TPMET at any of the
hyperoxic exposure times studied (Fig. 11C).

Fig. 11.Effect of duration of hyperoxic exposure on CoQ1, DQ, and TBOP+ reduction rates. CoQ1 (A), DQ (B), and
TBOP+ (C) reduction rates normalized to cell protein measured at 24, 48, and 72 h following initiation of
hyperoxic exposure. Reduction rates were measured using 600 μM ferricyanide and 50 μM CoQ1, 50 μM DQ, or
0.2 mg/ml TBOP and calculated as described in Fig. 4. Cell proteins (means ± SE) for the normoxic and hyperoxiaexposed cells were, respectively, 1.45 ± 0.05 and 1.50 ± 0.07 mg at 24 h, 1.67 ± 0.08 and 1.68 ± 0.06 mg at 48 h,
and 1.62 ± 0.05 and 1.67 ± 0.06 mg at 72 h; n = 4 experiments for each condition. Lactate dehydrogenase (LDH)
release (means ± SE) for the normoxic and hyperoxia-exposed cells were, respectively, 2.0 ± 0.3 and 1.6 ± 0.2%
at 24 h, 1.5 ± 0.2 and 1.8 ± 0.2% at 48 h, and 1.4 ± 0.2 and 1.7 ± 0.2% at 72 h. There were no significant
differences between the normoxic and hyperoxia-exposed cell %LDH release at any given time point (P > 0.05).
*P < 0.05, significantly different from normoxic cells at the corresponding time point. †P < 0.05, significantly
different from hyperoxia-exposed cells at 24 h. ‡P < 0.05, significantly different from hyperoxia-exposed cells at
48 h.

DISCUSSION
The results of the present study demonstrate that intact normoxic and hyperoxia-exposed bovine pulmonary
arterial endothelial cells reduce CoQ1, observed either as the appearance of CoQ1H2 in the extracellular medium
(Figs. 1B and 2) or as CoQ1-mediated reduction of the cell membrane-impermeant secondary electron acceptor
ferricyanide (Fig. 4). The apparent maximum CoQ1 reduction rate (Vmax) calculated from the Michaelis-Menten
model fit to the CoQ1-mediated ferricyanide reduction rates over a range of CoQ1 concentrations was
approximately twofold higher for the normoxic compared with hyperoxia-exposed cells (24.1 and 11.4
nmol·min−1·mg−1 cell protein, respectively) (Fig. 5). This difference apparently contributed to the observation
that the extracellular [CoQ1H2]/[CoQ1] ratio in the extracellular medium of normoxic cells was approximately
fourfold higher than that of the hyperoxia-exposed cells following incubation with 50 μM CoQ1.
The data also revealed a complex III-mediated CoQ1H2 oxidation process that contributed to net effect of the
cells on the extracellular CoQ1 redox status. This was manifested by the appearance of CoQ1 in the medium of
cells incubated with CoQ1H2, wherein the CoQ1 appearance rate could not be accounted for by
CoQ1H2 autooxidation (Fig. 3). In addition, cell-mediated CoQ1H2 oxidation was blocked by the complex III
inhibitors myxothiazol and antimycin A (Fig. 3). This was not unexpected, since complex III-mediated oxidation of
CoQ1H2 was the proposed mechanism for CoQ1-mediated restoration of electron transport in hepatocytes with
complex I dysfunction (12). Studies were not carried out to evaluate the impact of hyperoxic exposure on
CoQ1H2 oxidation kinetics, which would require additional studies of CoQ1H2 oxidation in the presence of
inhibitors of CoQ1 reduction. Thus the question remains whether a difference between normoxic and hyperoxiaexposed cell oxidation kinetics contributed to the differences between the net effects on CoQ1 redox status.
However, previous studies demonstrated that DQH2 was also oxidized via complex III in the pulmonary
endothelial cells and that oxidation kinetics in normoxic and hyperoxia-exposed cells were reasonably
comparable in the presence of dicumarol, the latter of which was included to suppress NQO1-mediated DQ
reduction for measurement of oxidation rates (28, 30). The study was interpreted to indicate that complex III
activity was not compromised in hyperoxia-exposed cells, which, if true, would imply that that the differences
between the impact of normoxic and hyperoxic-exposed cells on CoQ1 redox status would be predominately a
reflection of the differences in CoQ1 reduction rates.
Evidence for a role of complex I in intact cell-mediated CoQ1 reduction was revealed by the observation that
rotenone inhibited the CoQ1 (50 μM) reduction rates by ∼85 and ∼44% for the normoxic and hyperoxia-exposed
cells, respectively (Fig. 8). The decrease in complex I activity in the mitochondria-enriched fractions of hyperoxiaexposed cells was consistent with the decreases in both total and rotenone-sensitive CoQ1 reduction capacity in
the intact hyperoxia-exposed cells (21). Although to our knowledge an effect of hyperoxia to depress complex I

activity has not been observed previously in pulmonary endothelial cells, it has been reported for Chinese
hamster ovary (CHO) cells following a similar hyperoxic exposure protocol to that used in the present study (40).
Depression of complex I activity has also been observed in other cell types and tissues in response to prooxidant stimuli, including doxorubicin-treated endothelial cells (25). A recent study suggestive of mitochondrial
dysfunction in pediatric pulmonary hypertension reported that among the respiratory complexes, complex I was
the most severely affected in the two patients studied (6).
To evaluate the utility of CoQ1 as a quantitative probe of changes in complex I activity in intact cells, we
compared the impact of hyperoxia on intact cell CoQ1 reduction capacity, mitochondrial fraction complex I
activity, and intact cell oxygen consumption. First, the fractional decrease in intact cell rotenone-sensitive
CoQ1 reduction rate (77% lower than normoxic cells, Fig. 8) and complex I activity in mitochondrial fractions
(78% lower than normoxic cells, Fig. 10) was nearly the same. This suggested that the CoQ1 reduction rate in the
intact cells reflected the rate of electron flow through complex I. To obtain an independent estimate of the
maximum rate of electron flow through complex I in the intact cell, we measured cell oxygen consumption in the
presence of a mitochondrial uncoupler in the absence and presence of the complex I inhibitor rotenone (Fig.
9, A and B). Considering that reduction of CoQ1 to CoQ1H2 via complex I requires 2 moles of electrons per mole
of CoQ1 reduced, whereas O2 reduction via the electron transport chain utilizes 4 moles of electrons per mole
O2, there was a difference of 30 nmol·min−1·mg cell protein−1 between normoxic and hyperoxia-exposed cells
with respect to the rate of utilization of reducing equivalents for rotenone-sensitive CoQ1 reduction and a
difference of 24 nmol·min−1·mg cell protein−1 for uncoupled, rotenone-sensitive O2 reduction. These values are
reasonably close, supporting the concept that intact cell CoQ1 reduction rates, measured in the extracellular
medium under certain defined experimental conditions (e.g., saturating CoQ1 concentrations), can provide a
reasonable approximation of the magnitude of changes in mitochondrial complex I activity in response to
oxidative stress.
The intact cell complex I measurement using CoQ1 may be distinguished from measurements in isolated
mitochondria or submitochondrial particles in that it reflects not only the intrinsic activity of the complex but
also other factors contributing to its activity under a given set of physiological or pathophysiological conditions.
These may include a restriction in the availability of reducing equivalents produced via Krebs cycle enzymes, for
example, via aconitase inactivation observed in hyperoxic exposure of lung and lung A549 cells (20). In the
present study, the relationship between the effects of hyperoxia on complex I activity in the mitochondrial
fractions (78% lower than normoxic cells) and on coupled rotenone-sensitive oxygen consumption (78% lower
than normoxic cells) was reasonably consistent with that observed in a model of rotenone-induced complex I
deficiency in human osteosarcoma-derived cells (7). In that study, ∼80% inhibition of complex I activity was
associated with ∼60% decrease in total cellular oxygen consumption, wherein the latter decrease might have
been expected to be even larger if the rotenone-sensitive fraction were considered. The implication is that for
the hyperoxia-exposed cells, a defect in complex I provided a sufficient explanation for the depression in oxygen
consumption. In this regard, it is the combined information contained in measurements of oxygen consumption,
isolated mitochondrial complex I activity, and intact cell CoQ1 reduction capacity that can provide insight into
the role of complex I in mitochondrial dysfunction.
There were several indications that the effect of hyperoxia on complex I activity was not due to nonspecific
depression of cell metabolism or redox function. First, there was no detectable difference between the
cytochrome oxidase activities measured in the normoxic and hyperoxia-exposed cell mitochondrial fractions
(Fig. 10B). The relative insensitivity of cytochrome oxidase activity compared with complex I activity in the
hyperoxia-exposed cells was consistent with observations in bovine heart submitochondrial particles exposed to
various reactive oxygen species (ROS) (45). The observations that the cell protein and viability (%LDH release)
were equivalent for the normoxic and hyperoxia-exposed cells, as were the total LDH activities, wherein LDH

represents another cell redox enzyme, further suggested that the effect of hyperoxia was not as a widespread
nonspecific toxicant. This concept is consistent with the fact that the DQ reduction capacity was actually higher
in the hyperoxia-exposed than normoxic cells, as previously observed (28), whereas TPMET activity was
unaffected.
The basis for the selectivity of CoQ1, DQ and TBOP+ for reduction via complex I, NQO1, and the TPMET system
utilizing thiazine acceptors, respectively, is presumably their differing physical and/or chemical properties. TBOP
is so large that it is excluded from the cell and is thereby reduced predominately at the cell surface (9). That
CoQ1 acted as a complex I substrate in the intact cells might have been anticipated from its utility as an
amphipathic CoQ10 homolog in studies of complex I in mitochondria and submitochondrial fractions (16, 18, 33).
CoQ1 is reduced more rapidly than DQ via the NADH dehydrogenase activity of complex I in isolated
mitochondria and displays a higher degree of rotenone sensitivity, whereas DQ has been considered a relatively
“poor” acceptor for this enzyme (16, 18). The activity of CoQ1 compared with DQ as a complex I substrate is not
on the basis of solubility characteristics, which are comparable for the two quinones (water solubilities of 1.5
and 1.3 mM for DQ and CoQ1, respectively; log cyclohexane:H2O partition coefficients 2.45 and 2.65,
respectively), but has been attributed instead to steric factors (16, 18). With respect to the relative specificity of
NQO1 for the two quinones, although CoQ1 acts as a substrate for isolated NQO1, a marked preference was
observed for DQ as an NQO1 electron acceptor in the intact pulmonary endothelial cells in the present study.
This might have been anticipated based on quantitative structure activity studies showing that quinones with
van der Waals volume of <200 Å (DQ, 162.9 Å; CoQ1, 243.96 Å) behave as relatively “fast” NQO1 substrates
(high Kcat/Km) (1, 41). Thus the basis for the propensity for CoQ1 to act as an NQO1 substrate in studies of various
other cell types is not known and may be attributable in part to species differences in NQO1 electron acceptor
preference (17).
CoQ1 has also been suggested as a TPMET electron acceptor in human red blood cells, Hep G cells, and chick
neurons, although whether it is via the same TPMET system that utilizes thiazines (e.g., TBOP) is not known
(42, 44). The Hep G and red blood cells carried out both CoQ1 reduction and CoQ1H2 oxidation processes,
producing qualitatively similar effects on CoQ1 extracellular redox status to those seen in the present study (42).
However, to the extent that the two studies can be compared given the different experimental conditions, the
data suggested a substantially greater net CoQ1 reduction capacity for the red blood and Hep G cells than for the
pulmonary arterial endothelial cells in the present study, implying that the balance between the relative
contributions of CoQ1 reduction and CoQ1 oxidation reactions that produce the net effect in the extracellular
medium is different among the different cell types.
The rotenone-insensitive CoQ1 reduction mechanism was not identified or characterized other than that it
contributed a proportionally greater fraction of the total CoQ1 reduction capacity for the hyperoxia-exposed
than for the normoxic cells and that it did not appear to be NQO1. Given the variety of potential
CoQ1 reductases and the likelihood that expression and/or activity of any given one might also be sensitive to
oxidative stress, it is conceivable that a different complement of reductases contributes to the rotenoneinsensitive CoQ1 reduction component in the normoxic and hyperoxia-exposed cells. A difference in the
complement of contributing reductases at CoQ1 concentrations below ∼10 μM could also explain the difference
in apparent Km values for normoxic and hyperoxia-exposed cell CoQ1 reduction (Fig. 5). Of note is that the
reduction rates in Fig. 5 were obtained using ferricyanide in the absence of any inhibitors (e.g., rotenone),
thereby providing a measure of “net” CoQ1 reduction that does not reveal the identity or proportional
contributions of any contributing quinone reductases.
The deleterious effects of hyperoxia in the lung and pulmonary endothelium are generally accepted to be
mediated by production of excessive ROS (19, 39). Recent observations suggest that hyperoxia-induced injury in
pulmonary capillary endothelial cells in situ is triggered initially via ROS production at complex I and a relatively

delayed contribution of NADPH oxidase (10). Superoxide formation via complex I has also been associated with
development of ischemia-reperfusion injury in the heart and neurodegeneration in Parkinson's disease and
other conditions (24, 34). At the same time, complex I is susceptible to ROS-induced inactivation (13). Thus,
although on one hand the impact of hyperoxia on complex I may be interpreted as a manifestation of injury,
alternatively it might be viewed as an adaptive mechanism, analogous to the association of depressed complex I
activity with anesthetic preconditioning for protection from cardiac ischemia-reperfusion injury (38). Insofar as
mitochondria-derived ROS have been implicated as signaling molecules in endothelial responses to certain
oxidative stresses (e.g., hypoxia and hyperoxia), compromised complex I activity might affect such signaling
pathways, since it likely plays a direct or indirect role in mitochondrial ROS generation (10, 35). One might also
speculate a potential for secondary effects of altered ROS production on the activity and function of nitric oxide,
which has been implicated in regulation of respiration and mitochondrial ROS signaling in vascular endothelium
(35).
The pulmonary endothelium encounters various blood borne quinones as environmental, pharmacological,
physiological, and dietary components (11). Given its large perfused surface area and its position between the
venous and systemic arterial circulations, the pulmonary endothelium has the potential to play a key role in
determining the redox status of these substances in the blood, as exemplified by its impact on CoQ1 in the
extracellular medium in the present study. The implication is that for quinones accessible to pulmonary
endothelial redox enzymes for which they are substrates, and depending on the tissue permeability of the
oxidized and reduced forms, this endothelial function may have an impact on the redox status, and hence
bioactivity, of quinones not only in the lung but also in downstream organs. It follows that changes in pulmonary
endothelial complex I activity as a result of injury or adaptation may be reflected as alterations in the redox
status or disposition of redox active compounds that can permeate the pulmonary endothelial cell membrane
and undergo reactions involving complex I. For example, with regard to quinones that may be detoxified by twoelectron reduction via complex I, compromised complex I activity may promote generation of the generally
more toxic semiquinone. Finally, the study results suggest the potential utility of CoQ1 as a probe for
nondestructive measurements of complex I activity in the intact lung, analogous to the use of DQ for evaluation
of lung NQO1 activity.
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